160 related articles for article (PubMed ID: 14965358)
1. Antitumor activity of sugar-modified cytosine nucleosides.
Matsuda A; Sasaki T
Cancer Sci; 2004 Feb; 95(2):105-11. PubMed ID: 14965358
[TBL] [Abstract][Full Text] [Related]
2. Nucleosides and nucleotides. 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and -uracil1.
Hattori H; Nozawa E; Iino T; Yoshimura Y; Shuto S; Shimamoto Y; Nomura M; Fukushima M; Tanaka M; Sasaki T; Matsuda A
J Med Chem; 1998 Jul; 41(15):2892-902. PubMed ID: 9667977
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
[TBL] [Abstract][Full Text] [Related]
4. Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)-cytosine, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity.
Hattori H; Tanaka M; Fukushima M; Sasaki T; Matsuda A
J Med Chem; 1996 Dec; 39(25):5005-11. PubMed ID: 8960561
[TBL] [Abstract][Full Text] [Related]
5. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106)1: antitumor effect and mechanism of action.
Azuma A; Matsuda A; Sasaki T; Fukushima M
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):609-19. PubMed ID: 11563078
[TBL] [Abstract][Full Text] [Related]
6. Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in alkaline medium: formation of 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine and its antitumor activity.
Azuma A; Hanaoka K; Kurihara A; Kobayashi T; Miyauchi S; Kamo N; Tanaka M; Sasaki T; Matsuda A
J Med Chem; 1995 Aug; 38(17):3391-7. PubMed ID: 7650692
[TBL] [Abstract][Full Text] [Related]
7. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Liu XJ; Nowak B; Wang YQ; Plunkett W
Chin J Cancer; 2012 Aug; 31(8):373-80. PubMed ID: 22739266
[TBL] [Abstract][Full Text] [Related]
8. [Nucleoside kinases and new types of antitumor nucleosides].
Matsuda A
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1594-9. PubMed ID: 9309159
[TBL] [Abstract][Full Text] [Related]
9. Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil.
Takatori S; Kanda H; Takenaka K; Wataya Y; Matsuda A; Fukushima M; Shimamoto Y; Tanaka M; Sasaki T
Cancer Chemother Pharmacol; 1999; 44(2):97-104. PubMed ID: 10412942
[TBL] [Abstract][Full Text] [Related]
10. Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Galmarini CM; Mackey JR; Dumontet C
Leukemia; 2001 Jun; 15(6):875-90. PubMed ID: 11417472
[TBL] [Abstract][Full Text] [Related]
11. Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides.
Obata T; Endo Y; Tanaka M; Uchida H; Matsuda A; Sasaki T
Jpn J Cancer Res; 2001 Jul; 92(7):793-8. PubMed ID: 11473731
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of pyrimidine analogues and their nucleosides.
Daher GC; Harris BE; Diasio RB
Pharmacol Ther; 1990; 48(2):189-222. PubMed ID: 2293239
[TBL] [Abstract][Full Text] [Related]
13. Profiles of pyrimidine biosynthesis, salvage and degradation in disks of potato (Solanum tuberosum L.) tubers.
Katahira R; Ashihara H
Planta; 2002 Sep; 215(5):821-8. PubMed ID: 12244448
[TBL] [Abstract][Full Text] [Related]
14. New nucleoside analogs in the treatment of solid tumors.
Szafraniec SI; Stachnik KJ; Skierski JS
Acta Pol Pharm; 2004; 61(4):297-305. PubMed ID: 15575597
[TBL] [Abstract][Full Text] [Related]
15. Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
Niitsu N; Ishii Y; Matsuda A; Honma Y
Cancer Res; 2001 Jan; 61(1):178-85. PubMed ID: 11196157
[TBL] [Abstract][Full Text] [Related]
16. Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line.
Kazuno H; Sakamoto K; Fujioka A; Fukushima M; Matsuda A; Sasaki T
Cancer Sci; 2005 May; 96(5):295-302. PubMed ID: 15904471
[TBL] [Abstract][Full Text] [Related]
17. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Muggia F; Diaz I; Peters GJ
Expert Opin Investig Drugs; 2012 Apr; 21(4):403-8. PubMed ID: 22404148
[TBL] [Abstract][Full Text] [Related]
18. Nucleosides and nucleotides. 94. Radical deoxygenation of tert-alcohols in 1-(2-C-alkylpentofuranosyl) pyrimidines: synthesis of (2'S)-2'-deoxy-2'-C-methylcytidine, an antileukemic nucleoside.
Matsuda A; Takenuki K; Sasaki T; Ueda T
J Med Chem; 1991 Jan; 34(1):234-9. PubMed ID: 1992123
[TBL] [Abstract][Full Text] [Related]
19. Syntheses of 4'-C-ethynyl-beta-D-arabino- and 4'-C-ethynyl-2'-deoxy-beta-D-ribo-pentofuranosylpyrimidines and -purines and evaluation of their anti-HIV activity.
Ohrui H; Kohgo S; Kitano K; Sakata S; Kodama E; Yoshimura K; Matsuoka M; Shigeta S; Mitsuya H
J Med Chem; 2000 Nov; 43(23):4516-25. PubMed ID: 11087576
[TBL] [Abstract][Full Text] [Related]
20. Cellular pharmacology of gemcitabine.
Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
